Document is current

Article History

Received: 1 December 2021

Accepted: 26 October 2022

First Online: 16 November 2022

Declarations

:

: AGD receives royalties from publishing companies as an author of books and treatment manuals on child behavioral therapy and assessment manuals, including the treatment manuals evaluated in this trial. TB served in an advisory or consultancy role for ADHS digital, Infectopharm, Lundbeck, Medice, Neurim Pharmaceuticals, Oberberg GmbH, Roche, and Takeda. He received conference support or speaker’s fees from Medice and Takeda. He received royalities from Hogrefe, Kohlhammer, CIP Medien, Oxford University Press; the present work is unrelated to these relationships. CH receives royalties from a publishing company as the author of a treatment manual. MK receives royalties from publishing companies as an author of books. He served as PI or CI in clinical trials of Lundbeck, Pascoe, and Janssen-Cilag. He received grants from the BMBF, BMFSFJ, BZgA and Bundeswehr. He served as scientific advisor for Janssen. The present work is unrelated to the above grants and relationships. MD receives royalties from publishing companies as an author of books and treatment manuals on child behavioral therapy and of assessment manuals published by Beltz, Elsevier, Enke, Guilford, Hogrefe, Huber, Kohlhammer, Schattauer, Springer, and Wiley. He receives income as a consultant for Child Behavior Therapy at the National Association of Statutory Health Insurance Physicians. He also receives consulting income and research support from Lilly, Medice, Takeda, and eyelevel GmbH. DB served as an unpaid scientific advisor for an EU-funded neurofeedback trial unrelated to the present work. All other authors declare no conflict of interest.

: Ethical approval has been obtained for all study centers.

: Verbal and written consent was obtained from children and parents/caregivers.